ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO1030

Real-World Effectiveness of Sucroferric Oxyhydroxide in European Hemodialysis (HD) Patients: A 1-Year Retrospective Study

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Chazot, Charles, NephroCare Tassin-Charcot, Sainte Foy-Les-Lyon, France
  • Ferreira, Manuel A., NephroCare, Vila Franca de Xira, Portugal
  • Ramos, Rosa, Fresenius Medical Care, Bad Homburg, Germany
  • Di Benedetto, Attilio, NephroCare, Naples, Italy
  • Kagermeier, Birgit, Fresenius Medical Care, Contract Clinical Services, Bad Homburg, Germany
  • Feuersenger, Dr. Astrid, Fresenius Medical Care Deutschland GmbH, Bad Homburg v.d.H., Germany
  • Wolf, Melanie, Fresenius Medical Care Deutschland GmbH, Bad Homburg v.d.H., Germany
  • Arens, Hans-Juergen, Fresenius Medical Care Deutschland GmbH, Bad Homburg v.d.H., Germany
  • Walpen, Sebastian, Vifor Fresenius Medical Care Renal Pharma, Glattbrugg, Switzerland
  • Stuard, Stefano, Fresenius Medical Care, Bad Homburg, Germany

Retrospective analysis evaluated the effectiveness of the phosphate binder (PB), sucroferric oxyhydroxide (SO), for serum phosphorus (sP) control among European HD pts in routine practice.


De-identified data were extracted from a clinical database (EuCliD5) for adult HD pts (France, Italy, Spain, Portugal, Russia) newly prescribed SO between Jan 2015−Jan 2019 for up to 1 year. PB pill burden and sP were compared between baseline (BL; 3-month period prior to SO prescription) and 4 consecutive quarters of SO therapy (Q1−Q4) for the overall cohort and 3 subgroups: PB-naïve pts treated with SO monotherapy (mSO), and PB pre-treated pts either switched to SO monotherapy (PB→mSO), or who added SO to another PB (PB+SO).


The overall cohort comprised 1096 pts (mean age: 60.6 years; 65.8% male) including 796, 188 and 53 pts in the PB+SO, mSO, and PB→mSO groups. Comparing BL and Q1−Q4 for the overall cohort, SO provided consistent reductions in mean sP, and increased the % pts achieving sP target (≤5.5 mg/dL) (Fig.A). Of the 3 subgroups analyzed, mean BL sP levels were highest among PB+SO pts (5.9 mg/dL) and lowest among PB→mSO pts (5.43 mg/dL) (Fig.B). % of pts achieving sP target increased in all 3 subgroups during Q1−Q4, but to the greatest extent in the mSO and PB+SO groups. For PB+SO pts, sP improvements were achieved with a similar number of PB pills prescribed at BL prior to SO (6.5 vs. 6.2 pills/day at Q4). SO pill burden was low across all 3 subgroups (2.1−2.8 pills/day).


This real-world analysis suggests SO can improve sP control among HD pts either administered as monotherapy or add-on therapy to another PB, without increasing pill burden.


  • Commercial Support